Nuvation Bio, Inc.(NUVB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NUVB Nuvation Bio, Inc.

已收盘 07-06 16:00:00 EDT

5.60

-0.10

-1.75%

盘后5.52

-0.08-1.43%

19:50 EDT

最高5.94	最低5.55	成交量551.86万
今开5.77	昨收5.70	日振幅6.75%
总市值19.47亿	流通市值14.28亿	总股本3.48亿
成交额3,142万	换手率2.16%	流通股本2.55亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NUVB","market":"US","secType":"STK","nameCN":"Nuvation Bio, Inc.","latestPrice":5.6,"timestamp":1783368000000,"preClose":5.7,"halted":0,"volume":5518575,"hourTrading":{"tag":"盘后","latestPrice":5.52,"preClose":5.6,"latestTime":"19:50 EDT","volume":321784,"amount":1780809.7997,"timestamp":1783381811180,"change":-0.08,"changeRate":-0.014286,"amplitude":0.039286},"delay":0,"changeRate":-0.0175438596491229,"floatShares":254999999,"shares":347597289,"eps":-0.424745,"marketStatus":"已收盘","change":-0.1,"latestTime":"07-06 16:00:00 EDT","open":5.77,"high":5.935,"low":5.55,"amount":31424688.169672497,"amplitude":0.067544,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.424745,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783411200000},"marketStatusCode":5,"adr":0,"exchange":"NYSE","adjPreClose":5.7,"preHourTrading":{"tag":"盘前","latestPrice":5.75,"preClose":5.69,"latestTime":"09:12 EDT","volume":863,"amount":4954.742763,"timestamp":1783343522809,"change":0.06,"changeRate":0.010545,"amplitude":0.035149},"postHourTrading":{"tag":"盘后","latestPrice":5.52,"preClose":5.6,"latestTime":"19:50 EDT","volume":321784,"amount":1780809.7997,"timestamp":1783381811180,"change":-0.08,"changeRate":-0.014286,"amplitude":0.039286},"volumeRatio":0.367315,"impliedVol":1.0311,"impliedVolPercentile":0.3944},"requestUrl":"/m/hq/s/NUVB/tweets","defaultTab":"tweets","newsList":[{"id":"1162423314","title":"Nuvation Bio, Inc. 宣布全额行使绿鞋期权，完成2.875亿美元可转换优先票据发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1162423314","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162423314?lang=zh_cn&edition=full","pubTime":"2026-07-07 05:12","pubTimestamp":1783372320,"startTime":"0","endTime":"0","summary":"Nuvation Bio, Inc. 已宣布，在其2.875亿美元可转换优先票据的发行中，全额行使了绿鞋期权。此举意味着承销商已完全行使了额外购买票据的选择权，从而扩大了本次发行的总规模。这一操作通常旨在满足强劲的市场需求，并为公司带来更多的融资。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164453184","title":"Nuvation Bio宣布其治疗晚期ROS1阳性非小细胞肺癌药物Taletrectinib的上市授权申请在英国获确认","url":"https://stock-news.laohu8.com/highlight/detail?id=1164453184","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164453184?lang=zh_cn&edition=full","pubTime":"2026-06-29 20:00","pubTimestamp":1782734436,"startTime":"0","endTime":"0","summary":"Nuvation Bio, Inc. 宣布，其针对晚期ROS1阳性非小细胞肺癌的治疗药物Taletrectinib的上市授权申请已在英国获得验证。这一进展标志着该候选药物在欧洲监管审批流程中迈出了关键一步，为其未来在欧盟市场的潜在商业化铺平了道路。公司表示，将继续与监管机构密切合作，推进该药物的审评进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195390863","title":"Nuvation Bio与赛默飞世尔科技达成合作，将在美国本土生产用于ROS1阳性非小细胞肺癌的Ibtrozi®","url":"https://stock-news.laohu8.com/highlight/detail?id=1195390863","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195390863?lang=zh_cn&edition=full","pubTime":"2026-05-14 04:06","pubTimestamp":1778702784,"startTime":"0","endTime":"0","summary":"生物制药公司Nuvation Bio宣布，将与全球科学服务巨头赛默飞世尔科技建立合作关系，在美国本土进行其靶向药物Ibtrozi的生产制造。该药物旨在用于治疗ROS1阳性非小细胞肺癌患者。此次合作旨在利用赛默飞世尔科技在生物制药合同开发与生产领域的专业能力和规模化设施，以确保Ibtrozi稳定、高质量的供应链。ROS1阳性非小细胞肺癌存在明确的未满足临床需求，Ibtrozi的开发与生产进展备受关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112065292","title":"Nuvation Bio公司宣布：FDA受理Ibtrozi治疗晚期ROS1阳性非小细胞肺癌的补充新药申请 目标审评日期定为2027年1月4日","url":"https://stock-news.laohu8.com/highlight/detail?id=1112065292","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112065292?lang=zh_cn&edition=full","pubTime":"2026-05-06 20:01","pubTimestamp":1778068914,"startTime":"0","endTime":"0","summary":"Nuvation Bio公司近日披露重要监管进展，美国食品药品监督管理局（FDA）已正式受理其核心候选药物Ibtrozi针对晚期ROS1阳性非小细胞肺癌（NSCLC）的补充新药申请（sNDA）。这一关键里程碑触发了审评流程的启动，FDA已将此次申请的目标审评日期确定为2027年1月4日。\n此次受理标志着Ibtrozi在扩大适应症方面迈出了坚实一步，若最终获批，将为特定类型的晚期肺癌患者提供一种新的潜在治疗选择。公司正积极准备后续的审评沟通工作，以推动该疗法早日惠及患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143649041","title":"Nuvation Bio宣布FDA受理Ibtrozi®补充新药申请 更新晚期ROS1阳性非小细胞肺癌缓解持续时间数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1143649041","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143649041?lang=zh_cn&edition=full","pubTime":"2026-05-06 20:01","pubTimestamp":1778068884,"startTime":"0","endTime":"0","summary":"生物制药公司Nuvation Bio宣布，美国食品药品监督管理局（FDA）已正式受理其核心产品Ibtrozi®（Taletrectinib）的补充新药申请。此次申请的关键在于更新了该药物在治疗晚期ROS1阳性非小细胞肺癌患者中的缓解持续时间数据。\n这一监管里程碑标志着Ibtrozi®在肺癌靶向治疗领域迈出重要一步。最新提交的临床数据进一步验证了该药物为患者带来的持久临床获益，为后续审批流程奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144496494","title":"Nuvation Bio宣布国家综合癌症网络®将Taletrectinib（Ibtrozi®）纳入中枢神经系统肿瘤临床实践指南推荐方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1144496494","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144496494?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:01","pubTimestamp":1777291277,"startTime":"0","endTime":"0","summary":"生物制药公司Nuvation Bio宣布，国家综合癌症网络®（NCCN）正式将Taletrectinib（商品名Ibtrozi®）作为推荐治疗方案，纳入其中枢神经系统肿瘤临床实践指南。\n这一重要更新意味着该靶向药物获得了权威肿瘤学术组织对治疗中枢神经系统癌症的临床认可。指南的修订将为医疗专业人员提供基于最新循证医学证据的治疗决策支持。\nNuvation Bio专注于开发创新肿瘤疗法，此次Taletrectinib被纳入NCCN指南，标志着该药物在神经肿瘤领域临床应用价值获得重要突破。这一进展有望为特定中枢神经系统肿瘤患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170391581","title":"财报前瞻｜Nuvation Bio, Inc.本季营收预计增142.41%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1170391581","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170391581?lang=zh_cn&edition=full","pubTime":"2026-04-27 10:37","pubTimestamp":1777257444,"startTime":"0","endTime":"0","summary":"Nuvation Bio, Inc.将于2026年05月04日美股盘后发布季度财报，市场关注收入增长与费用控制的平衡，以及关键管线的商业化推进节奏。若本季度财报验证收入增速与EPS的拐点，机构普遍预期股价弹性将随催化兑现而提升，看多观点占据主导地位。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Nuvation Bio, Inc.本季营收预计增142.41%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129042403","title":"Nuvation Bio将于2026年5月4日公布2026年第一季度财报并举行业务进展说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1129042403","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129042403?lang=zh_cn&edition=full","pubTime":"2026-04-21 04:08","pubTimestamp":1776715693,"startTime":"0","endTime":"0","summary":"生物制药公司Nuvation Bio宣布，计划于2026年5月4日发布其2026年第一季度财务业绩报告。此次公告将同步更新公司最新业务动态，向投资者全面展示研发进展与战略规划。\n通过定期披露经营成果，企业能够增强市场透明度，维系投资者关系。此次财报发布将为企业全年的财务表现奠定重要基调。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100641726","title":"卫材与Nuvation Bio宣布欧洲药品管理局验证泰来替尼治疗晚期ROS1阳性非小细胞肺癌的上市授权申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1100641726","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100641726?lang=zh_cn&edition=full","pubTime":"2026-03-27 04:10","pubTimestamp":1774555835,"startTime":"0","endTime":"0","summary":"卫材制药与Nuvation Bio公司共同宣布，其针对晚期ROS1阳性非小细胞肺癌的治疗药物泰来替尼的上市授权申请，已正式获得欧洲药品管理局的验证。这一关键进展标志着该药物在欧洲监管审批流程中迈出重要一步，为患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617138698","title":"Nuvation Bio Inc.2025财年实现净利润-2.05亿美元，同比增加63.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617138698","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617138698?lang=zh_cn&edition=full","pubTime":"2026-03-08 00:01","pubTimestamp":1772899272,"startTime":"0","endTime":"0","summary":"3月8日，Nuvation Bio Inc.公布财报，公告显示公司2025财年净利润为-2.05亿美元，同比增加63.91%；其中营业收入为62.90百万美元，同比增加699.24%，每股基本收益为-0.60美元。从资产负债表来看，Nuvation Bio Inc.总负债2.89亿美元，其中短期债务17.19百万美元，资产负债比为2.06，流动比率为0.07。机构评级：截至2026年3月8日，当前有10家机构对Nuvation Bio Inc.目标价做出预测，其中目标均价为11.60美元，其中最低目标价为7.00美元，最高目标价为17.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260308000140a6ad6d33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260308000140a6ad6d33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617510519","title":"Nuvation Bio Inc.盘中异动 股价大涨5.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617510519","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617510519?lang=zh_cn&edition=full","pubTime":"2026-03-05 02:23","pubTimestamp":1772648603,"startTime":"0","endTime":"0","summary":"北京时间2026年03月05日02时23分，Nuvation Bio Inc.股票出现波动，股价快速上涨5.73%。截至发稿，该股报4.61美元/股，成交量310.185万股，换手率0.90%，振幅8.03%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为1.05%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域的未满足需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030502232395430596&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030502232395430596&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114154062","title":"Nuvation Bio将于2026年3月2日公布2025年第四季度及全年业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1114154062","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114154062?lang=zh_cn&edition=full","pubTime":"2026-02-18 05:07","pubTimestamp":1771362450,"startTime":"0","endTime":"0","summary":"Nuvation Bio, Inc. (NUVB) 宣布，公司计划于2026年3月2日发布2025财年第四季度及全年的财务业绩报告。此次公告还将包含最新的业务动态更新，为投资者提供公司运营状况的全面视角。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610531654","title":"Nuvation Bio Inc.盘中异动 股价大跌5.09%报5.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610531654","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610531654?lang=zh_cn&edition=full","pubTime":"2026-02-09 22:34","pubTimestamp":1770647673,"startTime":"0","endTime":"0","summary":"北京时间2026年02月09日22时34分，Nuvation Bio Inc.股票出现波动，股价快速下跌5.09%。截至发稿，该股报5.41美元/股，成交量30.7076万股，换手率0.09%，振幅8.56%。Nuvation Bio Inc.股票所在的生物技术行业中，整体跌幅为0.06%。其相关个股中，艾切托、Novabay Pharmaceuticals, Inc.、Lunai Bioworks Inc.涨幅较大，Agomab Therapeutics Nv、Liminatus Pharma, Inc.、Clearmind Medicine Inc.较为活跃，换手率分别为59.51%、27.30%、19.92%，振幅较大的相关个股有Cingulate Inc C/Wts 10/12/2026 、Genenta Science Spa、艾切托，振幅分别为34.95%、28.39%、18.35%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020922343395407670&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020922343395407670&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610654558","title":"Nuvation Bio启动第三阶段SIGMA试验，测试Safusidenib治疗IDH1突变型胶质瘤的效果Nuvation Bio Launches Phase 3 SIGMA Trial to Test Safusidenib for IDH1-Mutant Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2610654558","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610654558?lang=zh_cn&edition=full","pubTime":"2026-02-09 22:15","pubTimestamp":1770646500,"startTime":"0","endTime":"0","summary":"The SIGMA Trial will enroll participants globally and focus on individuals diagnosed with IDH1-mutant glioma. Safusidenib is designed to inhibit mutant IDH1 enzymes, which play a role in tumor growth by altering cellular metabolism. The study will measure key outcomes such as progression-free survival and overall survival rates among participants receiving safusidenib compared to those receiving standard treatment options.SIGMA 试验将在全球范围内招募参与者，并专注于确诊为 IDH1 突变型胶质瘤的个体。Safusidenib 旨在抑制突变的 IDH1 酶，这种酶通过改变细胞代谢在肿瘤生长中发挥作用。该研究将衡量接受 Safusidenib 的参与者与接受标准治疗的参与者之间的关键结果，如无进展生存期和总生存率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209221730a48f8fdc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209221730a48f8fdc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182910430","title":"Nuvation Bio启动Safusidenib治疗IDH1突变胶质瘤的关键全球III期Sigma试验(G203)","url":"https://stock-news.laohu8.com/highlight/detail?id=1182910430","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182910430?lang=zh_cn&edition=full","pubTime":"2026-02-09 21:02","pubTimestamp":1770642174,"startTime":"0","endTime":"0","summary":"Nuvation Bio公司正式宣布，针对其创新药物Safusidenib在IDH1突变型胶质瘤治疗领域的关键性全球III期Sigma临床试验（代号G203）已全面启动。这一里程碑式的进展标志着该疗法向商业化迈出决定性一步，为神经肿瘤领域带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608380022","title":"Nuvation Bio Inc.盘中异动 早盘急速拉升5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608380022","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608380022?lang=zh_cn&edition=full","pubTime":"2026-02-03 23:51","pubTimestamp":1770133887,"startTime":"0","endTime":"0","summary":"北京时间2026年02月03日23时51分，Nuvation Bio Inc.股票出现异动，股价快速拉升5.06%。截至发稿，该股报5.92美元/股，成交量120.304万股，换手率0.35%，振幅6.39%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.41%。其相关个股中，Liminatus Pharma Inc C/Wts 30/04/2030 、Jasper Therapeutics Inc C/Wts 24/09/2026 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Cdt Equity Inc.、Pmgc Holdings Inc.、Liminatus Pharma, Inc.较为活跃，换手率分别为644.47%、592.12%、53.55%，振幅较大的相关个股有Liminatus Pharma Inc C/Wts 30/04/2030 、Jasper Therapeutics Inc C/Wts 24/09/2026 、Briacell Therapeutics Corp C/Wts 26/02/2026，振幅分别为70.33%、40.89%、32.58%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203235127953fa8b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203235127953fa8b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604161129","title":"Nuvation Bio Inc.盘中异动 临近收盘快速下挫5.03%报5.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604161129","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604161129?lang=zh_cn&edition=full","pubTime":"2026-01-17 04:34","pubTimestamp":1768595680,"startTime":"0","endTime":"0","summary":"北京时间2026年01月17日04时34分，Nuvation Bio Inc.股票出现异动，股价大幅下挫5.03%。截至发稿，该股报5.83美元/股，成交量359.583万股，换手率1.05%，振幅6.68%。Nuvation Bio Inc.股票所在的生物技术行业中，整体跌幅为0.18%。其相关个股中，Jaguar Health, Inc.、Immunitybio, Inc.、Pasithea Therapeutics Corp C/Wts 12/08/2026 涨幅较大，Jaguar Health, Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为3486.55%、220.64%、138.72%，振幅较大的相关个股有Jaguar Health, Inc.、Novabay Pharmaceuticals, Inc.、Moolec Science Sa C/Wts 30/01/2028，振幅分别为112.49%、52.66%、48.70%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011704344097a22701&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011704344097a22701&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197728511","title":"Nuvation Bio公司：晚期ROS1+非小细胞肺癌治疗药物上市许可申请预计2026年上半年在欧洲提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1197728511","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197728511?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:33","pubTimestamp":1768221217,"startTime":"0","endTime":"0","summary":"Nuvation Bio公司宣布，其针对晚期ROS1阳性非小细胞肺癌（NSCLC）的治疗药物上市许可申请（MAA），预计将于2026年上半年在欧洲提交。这一进展标志着公司在肿瘤治疗领域的重要里程碑，有望为特定肺癌患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518303271","title":"Nuvation Bio Inc.盘中异动 股价大跌10.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518303271","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518303271?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:33","pubTimestamp":1741613585,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时33分，Nuvation Bio Inc.股票出现波动，股价急速下跌10.84%。截至发稿，该股报1.80美元/股，成交量4.4904万股，换手率0.01%，振幅3.17%。Nuvation Bio Inc.股票所在的生物技术行业中，整体跌幅为0.08%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213305abf2fcdb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213305abf2fcdb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DDC","BK4231","ADC","NUVB","BK4212","BK4007","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518819822","title":"Nuvation Bio Inc.2024财年实现净利润-5.68亿美元，同比减少649.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518819822","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518819822?lang=zh_cn&edition=full","pubTime":"2025-03-10 00:01","pubTimestamp":1741536087,"startTime":"0","endTime":"0","summary":"3月10日，Nuvation Bio Inc.公布财报，公告显示公司2024财年净利润为-5.68亿美元，同比减少649.34%；其中营业收入为7.87百万美元，每股基本收益为-2.11美元。从资产负债表来看，Nuvation Bio Inc.总负债76.84百万美元，其中短期债务7.95百万美元，资产负债比为0.08，流动比率为0.10。机构评级：截至2025年3月10日，当前有5家机构对Nuvation Bio Inc.目标价做出预测，其中目标均价为7.40美元，其中最低目标价为5.00美元，最高目标价为11.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000327a26898ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000327a26898ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NUVB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0189},{"period":"1month","weight":0.1633},{"period":"3month","weight":0.2925},{"period":"6month","weight":-0.3357},{"period":"1year","weight":1.7805},{"period":"ytd","weight":-0.3638}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung , M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco .","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.099824},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.044723},{"month":3,"riseRate":0.5,"avgChangeRate":0.083814},{"month":4,"riseRate":0.5,"avgChangeRate":0.010626},{"month":5,"riseRate":0.666667,"avgChangeRate":0.014611},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.044383},{"month":7,"riseRate":0.666667,"avgChangeRate":0.055514},{"month":8,"riseRate":0.6,"avgChangeRate":0.013694},{"month":9,"riseRate":0.5,"avgChangeRate":-0.038205},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.016548},{"month":11,"riseRate":0.5,"avgChangeRate":0.163132},{"month":12,"riseRate":0.666667,"avgChangeRate":0.061496}],"exchange":"NYSE","name":"Nuvation Bio, Inc.","nameEN":"Nuvation Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvation Bio, Inc.(NUVB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Nuvation Bio, Inc.(NUVB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Nuvation Bio, Inc.,NUVB,Nuvation Bio, Inc.股票,Nuvation Bio, Inc.股票老虎,Nuvation Bio, Inc.股票老虎国际,Nuvation Bio, Inc.行情,Nuvation Bio, Inc.股票行情,Nuvation Bio, Inc.股价,Nuvation Bio, Inc.股市,Nuvation Bio, Inc.股票价格,Nuvation Bio, Inc.股票交易,Nuvation Bio, Inc.股票购买,Nuvation Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvation Bio, Inc.(NUVB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Nuvation Bio, Inc.(NUVB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}